At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Vandetanib (ZD6474) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
In Brief
A Phase 2 clinical trial evaluating Vandetanib (ZD6474) and Docetaxel for Advanced Breast Cancer. Completed, enrolled 64 participants across 12 sites in 5 countries.
Detailed Summary
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesHungary, South Africa, Spain, Sweden, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
Primary CompletionJun 2007
First PostedJun 2007
Study CompletionJan 2009
TodayJul 2026
First PostedJun 29, 2007
Enrollment StartJan 1, 2006
Primary CompletionJun 1, 2007
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.0 years ago
Interventions
Vandetanib (ZD6474)drug
once daily oral dose
Docetaxeldrug
intravenous infusion